Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Photobiomodulation Therapy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: Role in Toxicities Prevention

  • Margherita Rotondi1
  • Roger Sun1,2
  • Houssam EL-Masri1
  • Giuseppe Facondo3
  • Andreea Cabulca1
  • Nahla Belattar1
  • Gabriela Dumitrescu1
  • Eric Deutsch1,2
  • Camelia Billard-Sandu1
  1. 1Department of Radiation Oncology, Institute Gustave Roussy, 94805 Villejuif, France
  2. 2INSERM, Radiothérapie Molèculaire et Innovation Thérapeutique, 94805 Villejuif, France
  3. 3Department of Radiation Oncology, Hospital Santa Maria della Misericordia, 33100 Udine, Italy
Read full textPDFDOICite

Abstract

Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) is frequently associated with severe acute toxicities that compromise treatment adherence and quality of life. This study evaluated the effectiveness of photobiomodulation (PBM) in reducing CRT-induced toxicities in a real-world cohort. Methods: Between May 2021 and July 2024, we retrospectively analyzed 117 HNC patients treated with definitive or adjuvant CRT and concomitant PBM: a non-invasive application of red or near-infrared light to cutaneous and mucosal surfaces to modulate inflammatory responses, using 620/820 nm or 650 nm devices, with irradiation times of 2–12 min and energy densities of 3–12 J/cm2 according to the treatment protocol. Toxicities were graded according to CTCAE v 5.0 at baseline, during treatment, at treatment completion, and throughout follow-up. Associations with toxicity were assessed with logistic regression for repeated measurements (generalized estimating equations). Patients were stratified according to PBM exposure (<10 vs. ≥10 sessions). Results: Median follow-up was 16 months. At treatment completion, grade 2–3 oral mucositis and radiodermatitis occurred in 38.5% and 25.6% of patients, respectively, both lower than rates reported in historical cohorts without PBM. Patients receiving ≥10 PBM sessions (72 pts) experienced significantly lower rates of grade 2–3 odynophagia at treatment completion (16.7% vs. 42.2%, p = 0.005) and persistent dysphagia at the last follow-up (12.5% vs. 33.3%, p = 0.009). PBM exposure was not associated with significant differences in weight loss, progression-free survival, or overall survival. Conclusions: This study provides real-world data on toxicity outcomes among HNC patients receiving PBM, with lower rates of selected toxicities observed among patients receiving ≥10 PBM sessions. Although the retrospective design and lack of a control group limit causal inference, these findings provide a strong rationale for prospective randomized trials to define the optimal PBM schedule and validate its clinical impact.

Related

  1. Extraoral Versus Intraoral Photobiomodulation for the Prevention of Oral Mucositis in Pediatric Patients Undergoing High-Dose Methotrexate Chemotherapy.
    Mariana Lena Sassi, Nicoly Ghilardi Cardoso, Rafael Zancan Mobile +7
    Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric DentistryPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Incidence of Nausea and Vomiting in Patients With Cervical Cancer Undergoing Chemoradiotherapy With Steroid-Sparing
    TAKUMA MATSUMOTO, KENSUKE YOSHIDA, MASAKI NAKAI +15
    In VivoPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaPMC
  3. High-risk profile for perioperative diabetic ketoacidosis in patients undergoing femoral fracture surgery and prevention implications
    Kaiwei Chen, Boqi Geng, Hongxi Mo +9
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref
  4. Photobiomodulation therapy combined with a static magnetic field in critically ill patients receiving invasive mechanical ventilation: protocol for a multicentre randomised triple-blind placebo-controlled trial.
    Ernesto Cesar Pinto Leal-Junior, Amanda Lima Pereira, Heliodora Leão Casalechi +5
    BMJ openPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCCrossref
  5. Reply to de la Barra Ortiz, H.A.; Chamorro Lange, C.H. Comment on “Alayat et al. The Effectiveness of Photobiomodulation Therapy on Pain and Function in Patients with Patellofemoral Pain Syndrome—A Systematic Review and Meta-Analysis. J. Clin. Med. 2026, 15, 20”
    Mohamed Salaheldien Alayat, Roaa A. Sroge, Abdulaziz Awali +6
    Journal of clinical medicinePeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{rotondi2026photobiomodulation,
  title = {{Photobiomodulation Therapy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: Role in Toxicities Prevention}},
  author = {Margherita Rotondi and Roger Sun and Houssam EL-Masri and Giuseppe Facondo and Andreea Cabulca and Nahla Belattar and Gabriela Dumitrescu and Eric Deutsch and Camelia Billard-Sandu},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15207968},
  url = {https://www.mdpi.com/2077-0383/15/20/7968},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Photobiomodulation Therapy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: Role in Toxicities Prevention
AU  - Margherita Rotondi
AU  - Roger Sun
AU  - Houssam EL-Masri
AU  - Giuseppe Facondo
AU  - Andreea Cabulca
AU  - Nahla Belattar
AU  - Gabriela Dumitrescu
AU  - Eric Deutsch
AU  - Camelia Billard-Sandu
PY  - 2026
DA  - 2026/10/01
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15207968
UR  - https://www.mdpi.com/2077-0383/15/20/7968
AB  - Background: Chemoradiotherapy (CRT) for head and neck cancer (HNC) is frequently associated with severe acute toxicities that compromise treatment adherence and quality of life. This study evaluated the effectiveness of photobiomodulation (PBM) in reducing CRT-induced toxicities in a real-world cohort. Methods: Between May 2021 and July 2024, we retrospectively analyzed 117 HNC patients treated with definitive or adjuvant CRT and concomitant PBM: a non-invasive application of red or near-infrared light to cutaneous and mucosal surfaces to modulate inflammatory responses, using 620/820 nm or 650 nm devices, with irradiation times of 2–12 min and energy densities of 3–12 J/cm2 according to the treatment protocol. Toxicities were graded according to CTCAE v 5.0 at baseline, during treatment, at treatment completion, and throughout follow-up. Associations with toxicity were assessed with logistic regression for repeated measurements (generalized estimating equations). Patients were stratified according to PBM exposure (<10 vs. ≥10 sessions). Results: Median follow-up was 16 months. At treatment completion, grade 2–3 oral mucositis and radiodermatitis occurred in 38.5% and 25.6% of patients, respectively, both lower than rates reported in historical cohorts without PBM. Patients receiving ≥10 PBM sessions (72 pts) experienced significantly lower rates of grade 2–3 odynophagia at treatment completion (16.7% vs. 42.2%, p = 0.005) and persistent dysphagia at the last follow-up (12.5% vs. 33.3%, p = 0.009). PBM exposure was not associated with significant differences in weight loss, progression-free survival, or overall survival. Conclusions: This study provides real-world data on toxicity outcomes among HNC patients receiving PBM, with lower rates of selected toxicities observed among patients receiving ≥10 PBM sessions. Although the retrospective design and lack of a control group limit causal inference, these findings provide a strong rationale for prospective randomized trials to define the optimal PBM schedule and validate its clinical impact.
SN  - 2077-0383
ER  -